Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3648)	12/15/2005 5:09:10 PM
From: former_pgs	Read Replies (2) \| Respond to of 12215

speedel: They have a renin inhibitor that is soon to be filed in the US in 1q 06; Europe in late 2006. Renin is upstream of ACE inhibitors (billion+ dollar market) and angiotensin receptor blockers (ARB; another billion + dollar market) for hypertension. The biological pathway is rock solid. Project is in collaboration with novartis and speedel stands to make royalties. Couple more products in the clinic. It's my new pet.